Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730439 | 0.97 | CYP2B6 (0.38) | CYP2B6PIK3CD | |
| SCHEMBL15730428 | 0.92 | PIK3CD (0.35) | CYP2B6PIK3CD | |
| SCHEMBL13204764 | 0.85 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL24603308 | 0.80 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL21099432 | 0.79 | CYP2B6 (0.39) | CYP2B6 | |
| SCHEMBL18270403 | 0.78 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL23841888 | 0.76 | CHRM2 (0.31) | — | |
| SCHEMBL10224599 | 0.76 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL18270414 | 0.74 | HRH3 (0.36) | PIK3CD | |
| SCHEMBL23386198 | 0.74 | CYP2B6 (0.34) | CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3985000-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | Chengdu Zenitar Biomedical Technology Co., Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11154563-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-10-26 | — | — | US | disclosed |
| EP-3571208-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2019-11-07 | — | — | US | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850225-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110294813-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SHIONOGI & CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| US-7998992-B2 | Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998992-B2 | Oxazolidinone derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100113448-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113448-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-1395587-A4 | PROCESS FOR THE PREPARATION OF IMIPENEM | RANBAXY LAB LTD (IN) | 2004-09-15 | — | — | EP | disclosed |
| EP-1395587-A1 | PROCESS FOR THE PREPARATION OF IMIPENEM | Ranbaxy Laboratories Limited (IN) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094828-A1 | PROCESS FOR THE PREPARATION OF IMIPENEM | RANBAXY LABORATORIES LIMITED (IN) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CYP2B6 907/4885PIK3CD 506/4885 |
| US-20110294813-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD17B3, HSD17B1, HSD3B1 | CYP2B6 168/4885PIK3CD 2866/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP2B6 3570/4885PIK3CD 3272/4885 |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | CYP2B6 836/4885PIK3CD 258/4885 |
| US-11154563-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP2B6 3826/4885PIK3CD 3174/4885 |
| US-20100113448-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD17B3, HSD17B1, HSD3B1 | CYP2B6 168/4885PIK3CD 2866/4885 |
| US-20190336515-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | CYP2B6 3826/4885PIK3CD 3174/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | CYP2B6 907/4885PIK3CD 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.